Moderna MRNA Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 178.2%-31.1pp | 210.2%+32.5pp | 209.6%+55.2pp | 228.8%+104pp | 209.4%+60.4pp | |
| Operating margin | -573%-189pp | -537%-170pp | -500.8%-194pp | -398.7%-116pp | -384.3%-198pp | |
| Net margin | -522.6%-138pp | -484.8%-86.2pp | -449.6%-89.1pp | -358.1%-7.6pp | -384.2%-166pp | |
| Returns | ||||||
| Return on equity | -122.2%-2.4pp | -115%+14.5pp | -114.9%+15.7pp | -104.8%+28.6pp | -119.8%-35.7pp | |
| Return on invested capital | -145.8%-14.7pp | -138.4%-6.6pp | -138.5%-13.9pp | -127.7%-7.1pp | -131.1%-51.0pp | |
| Efficiency | ||||||
| Asset turnover | 0.7×-0.3× | 0.7×-0.3× | 0.8×-0.3× | 0.9×-0.3× | 1×-0.4× | |
| Liquidity | ||||||
| Current ratio | 13.6×-2.8× | 15.4×-0.8× | 15.7×-0.2× | 16.2×+2.2× | 16.4×+3.1× | |
| Leverage | ||||||
| Debt-to-equity | 0.5×+0.1× | 0.4×0.0× | 0.3×-0.1× | 0.3×-0.1× | 0.4×0.0× | |
| Per Share | ||||||
| Book value per share | $89.14-22.4% | $96.46-21.1% | $102.61-21.2% | $108.58-19.9% | $114.86-23.2% | |
| Valuation | ||||||
| Market capitalization | $52.08B-46.9% | $42.9B-66.5% | $47.38B-68.4% | $63.02B-61.5% | $98.16B-40.3% | |
| Price / sales | 22.9×+0.4× | 17.2×-9.7× | 16.3×-11.3× | 16.8×-10.0× | 22.5×+0.4× | |
| Price / book | 6.2×-2.4× | 4.6×-6.1× | 4.7×-7.2× | 5.8×-6.9× | 8.6×-3.0× |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Moderna's profit margins?
- Moderna (MRNA) runs a 22.1% gross margin and a -153.3% operating margin, with a -143.6% net margin.
- Where do Moderna's ratios come from?
- Every ratio is computed from Moderna's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
